• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA’s Real-World Data Initiative Announces Its First Partners

EMA’s Real-World Data Initiative Announces Its First Partners

December 5, 2022

The first group of data partners has been selected for the European Medicines Agency’s (EMA) Data Analysis and Real-World Interrogation Network (DARWIN EU). These organizations will contribute healthcare data that will be used to generate real-world evidence (RWE) to support EMA regulatory decisions and reviews.

With the selection of these organizations, the agency said it has launched the first three studies under the DARWIN EU project. One study is focused on the epidemiology of rare blood cancers, the second assesses the use of valproate, an anticonvulsant, and the third is evaluating antibiotics with antimicrobial resistance in mind.

The initial partners, which include hospitals, universities, biobanks and patient registries, are as follows:

  • Auria Clinical Informatics (Finland);
  • Bordeaux University Hospital (France);
  • University of Oxford’s Clinical Practice Research Datalink (UK);
  • University of Tartu’s Estonian Biobank (Estonia);
  • Consorci Mar Parc de Salut Barcelona and Fundació Institut Hospital del Mar d’Investigacions Mèdiques’ Institut Municipal Assistència Sanitària Information System (Spain);
  • Integrated Primary Care Information (The Netherlands);
  • Integraal Kankercentrum Nederland’s Netherlands Cancer Registry (The Netherlands); and
  • Fundación Instituto Universitario para la Investigación en Atención Primaria de Salud Jordi Gol i Gurina’s Sistema d’Informació per al Desenvolupament de la Investigació en Atenció Primària (Spain).

There are more data partners to come, EMA said, with plans for adding at least ten new partners each year. In 2023, the agency will invite interested parties to apply to participate in the initiative.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing